Top

International Ophthalmology

Published in:

01-06-2018 | Original Paper

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Authors: T. Barth, F. Zeman, H. Helbig, M.-A. Gamulescu

Published in: International Ophthalmology | Issue 3/2018

Abstract

Purpose

To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections.

Methods

Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed.

Results

Eleven women and five men with a mean age of 35 years (SD 11, range 16–56 years) received intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1–9) were given per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both substances. The mean follow-up was 15 months (SD 11, range 6–40 months). BCVA improved in eight eyes (mean Δ +2.8 lines), remained stable in four eyes and decreased in four eyes (mean Δ −4.3 lines).

Conclusions

CNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV.

Amer R, Lois N (2011) Punctate inner choroidopathy. Surv Ophthalmol 56(1):36–53CrossRefPubMed

Zhang H, Liu Z, Sun P, Gu F (2012) Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: results of a 1-year prospective trial. Retina 32(6):1106–1113CrossRefPubMed

Campos J, Campos A, Mendes S, Neves A, Beselga D, Castro Sousa JP (2014) Punctate inner choroidopathy: a systematic review. Med Hypothesis Discov Innov Ophthalmol 3(3):76–82PubMedPubMedCentral

Watzke RC, Packer AJ, Folk JC, Benson WE, Borgess D, Ober RR (1984) Punctate inner choroidopathy. Am J Ophthalmol 98(5):572–584CrossRefPubMed

Leung TG, Moradi A, Liu D, Nguyen QD, Dunn JP, Burkholder B, Butler NJ, Ostheimer T, Thorne JE (2014) Clinical features and incidence rate of ocular complications in punctate inner choroidopathy. Retina 34(8):1666–1674CrossRefPubMed

Diaz RI, Sigler EJ, Rafieetary MR, Calzada JI (2015) Ocular histoplasmosis syndrome. Surv Ophthalmol 60:279–295CrossRefPubMed

Amaro MH, Muccioli C, Abreu MT (2007) Ocular histoplasmosis-like syndrome: a report from a nonendemic area. Arq Bras Oftalmol 70(4):577–580CrossRefPubMed

Watzke RC, Klein ML, Wener MH (1998) Histoplasmosis-like choroiditis in a nonendemic area: the northwest United States. Retina 18(3):204–212CrossRefPubMed

Essex RW, Wong J, Fraser-Bell S, Sandbach J, Tufail A, Bird AC, Dowler J (2010) Punctate inner choroidopathy: clinical features and outcomes. Arch Ophthalmol 128(8):982–987CrossRefPubMed

10.

Chatterjee S, Gibson JM (2003) Photodynamic therapy: a treatment option in choroidal neovascularisation secondary to punctate inner choroidopathy. Br J Ophthalmol 87(7):925–927CrossRefPubMedPubMedCentral

11.

Brueggeman RM, Noffke AS, Jampol LM (2002) Resolution of punctate inner choroidopathy lesions with oral prednisone therapy. Arch Ophthalmol 120(7):996CrossRefPubMed

12.

Gerstenblith AT, Thorne JE, Sobrin L, Do DV, Shah SM, Foster CS, Jabs DA, Nguyen QD (2007) Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology 114(6):1201–1204CrossRefPubMed

13.

Patel KH, Birnbaum AD, Tessler HH, Goldstein DA (2011) Presentation and outcome of patients with punctate inner choroidopathy at a tertiary referral center. Retina 31(7):1387–1391CrossRefPubMed

14.

Olsen TW, Capone A, Sternberg P, Grossniklaus HE, Martin DF, Aaberg TM (1996) Subfoveal choroidal neovascularization in punctate inner choroidopathy. Surgical management and pathologic findings. Ophthalmology 103(12):2061–2069CrossRefPubMed

15.

Brown J, Folk JC, Reddy CV, Kimura AE (1996) Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 103(7):1100–1105CrossRefPubMed

16.

Wachtlin J, Heimann H, Behme T, Foerster MH (2003) Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe’s Arch Clin Exp Ophthalmol 241:899–906CrossRef

17.

Carneiro AM, Silva RM, Veludo MJ, Barbosa A, Ruiz-Moreno JM, Falcao MS, Brandao EM, Falcao-Reis FM (2011) Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia. Ophthalmologica 225(2):81–88CrossRefPubMed

18.

Rishi P, Gupta A, Rishi E, Shah BJ (2013) Choroidal neovascularization in 36 eyes of children and adolescents. Eye 27(10):1158–1168CrossRefPubMedPubMedCentral

19.

Schadlu R, Blinder KJ, Shah GK, Holekamp NM, Thomas MA, Grand MG, Engelbrecht NE, Apte RS, Joseph DP, Prasad AG, Smith BT, Sheybani A (2008) Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 145(5):875–878CrossRefPubMed

20.

Campos J, Campos A, Beselga D, Mendes S, Neves A, Sousa JP (2013) Punctate inner choroidopathy: a clinical case report. Case Rep Ophthalmol 4(3):155–159CrossRefPubMedPubMedCentral

21.

Hohberger B, Rudolph M, Bergua A (2015) Choroidal neovascularization associated with punctate inner choroidopathy: combination of intravitreal anti-VEGF and systemic immunosuppressive therapy. Case Rep Ophthalmol 6(3):385–389CrossRefPubMedPubMedCentral

22.

Mangat SS, Ramasamy B, Prasad S, Walters G, Mohammed M, Mckibbin M (2011) Resolution of choroidal neovascularization secondary to punctate inner choroidopathy (PIC) with intravitreal anti-VEGF agents: a case series. Semin Ophthalmol 26(1):1–3CrossRefPubMed

23.

Vossmerbaeumer U, Spandau UHM, Baltz SV, Wickenhaeuser A, Jonas JB (2008) Intravitreal bevacizumab for choroidal neovascularisation secondary to punctate inner choroidopathy. Clin Exp Ophthalmol 36(3):292–294CrossRefPubMed

24.

Weiss S, Winter R, Meyer MW (2012) Punctate inner choroidopathy—Improvement in vision after anti-VEGF and photodynamic therapy. An 18-month follow-up control. Ophthalmologe 109(2):149–154CrossRefPubMed

25.

Chan W, Lai TYY, Liu DTL, Lam DSC (2007) Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 143(6):977–983CrossRefPubMed

26.

Menezo V, Cuthbertson F, Downes SM (2010) Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy. Retina 30(9):1400–1404CrossRefPubMed

27.

Mansour AM, Mackensen F, Arevalo JF, Ziemssen F, Mahendradas P, Mehio-Sibai A, Hrisomalos N, Lai TY, Dodwell D, Chan WM, Ness T, Banker AS, Pai SA, Berrocal MH, Tohme R, Heiligenhaus A, Bashshur ZF, Khairallah M, Salem KM, Hrisomalos FN, Wood MH, Heriot W, Adan A, Kumar A, Lim L, Hall A, Becker M (2008) Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 146(3):410–416CrossRefPubMed

28.

Arevalo JF, Adan A, Berrocal MH, Espinoza JV, Maia M, Wu L, Roca JA, Quiroz-Mercado H, Ruiz-Moreno JM, Serrano MA (2011) Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Retina 31(2):353–363CrossRefPubMed

29.

Winterhalter S, Joussen AM, Pleyer U, Stübiger N (2012) Inflammatory choroidal neovascularisations. Klin Monatsbl Augenheilkde 229(9):897–904CrossRef

30.

Pachydaki SI, Jakobiec A, Bhat P, Sobrin L, Michaud NA, Seshan SV, D’Amico DJ (2012) Surgical management and ultrastructural study of choroidal neovascularization in punctate inner choroidopathy. J Ophthal Inflamm Infect 2:29–37CrossRef

31.

Neri P, Manoni M, Fortuna C, Lettieri M, Mariotti C, Giovannini A (2010) Association of systemic steroids and mycophenolate mofetil as rescue therapy for uveitic choroidal neovascularization unresponsive to the traditional immunesuppressants: interventional case series. Int Ophthalmol 30:583–590CrossRefPubMed

32.

Spaide RF (1999) Choroidal neovascularization in younger patients. Curr Opin Ophthalmol 10(3):177–181CrossRefPubMed

Title: Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy
Authors: T. Barth
F. Zeman
H. Helbig
M.-A. Gamulescu
Publication date: 01-06-2018
Publisher: Springer Netherlands
Published in: International Ophthalmology / Issue 3/2018
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-017-0536-0

ACC 2024 Congress

Springer Medicine

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Association of Single Nucleotide Polymorphisms in XRCC1 (194) and XPD (751) with Age-related cataract

Comparative study of visual function and ocular aberrations of two different one-piece designed hydrophilic acrylic intraocular lens

Fulminant proliferative diabetic retinopathy in the non-photocoagulated eye following acute renal failure

Manifestation of meibomian gland dysfunction in patients with Sjögren’s syndrome, non-Sjögren’s dry eye, and non-dry eye controls

Subconjunctival hemorrhage and vision loss after regional ocular anesthesia

Fine mapping of chromosome 9 locus associated with congenital cataract